Interestingly, we observed an overall decrease in levels of IgM and IgG anti-SARS-CoV-2 proteins in the hematologic cancer patients that would die from COVID-19 (Figures 4B, C), while no changes were observed in IgA levels (Figure 4A). The gene discussed is CD79A; the disease is COVID-19.